Magnetic resonance in medicine · 2026
Dynamic Contrast Enhanced-Magnetic Resonance Fingerprinting (DCE-MRF) Improves Detection of Induced Vascular Perfusion Reduction in a Mouse Breast Cancer Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
MacAskill Christina J, Erokwu Bernadette O, Zhu Yuran, Wang Guanhua, Dupuis Andrew, Schiemann Barbara J, Ramamurthy Gopalakrishnan, Dhakan Chetan B, Kavran Michael, Wu Chunying, Schiemann William P, Sun Yilun, Griswold Mark A, Yu Xin, Pagel Mark D, Flask Chris A
Аннотация
PURPOSE: Dynamic contrast-enhanced MRI (DCE-MRI) can assess tumor perfusion using pharmacokinetic models. However, poor DCE-MRI reproducibility from reliance on conventional T1-weighted MRI has limited clinical translation. We evaluated whether Dynamic Contrast Enhanced-Magnetic Resonance Fingerprinting (DCE-MRF), which directly generates quantitative T1 relaxation time constant maps, provides improved precision and statistical power for detecting treatment-induced vascular changes compared to conventional DCE-MRI.
METHODS: Twenty female mice bearing orthotopic 4 T1 breast tumors were randomly assigned to DCE-MRF (n = 12) or conventional DCE-MRI (n = 8) cohorts. Both methods acquired matched spatial and temporal resolution (23-s) T1 measurements at baseline, 3 h, and 48 h post-treatment with combretastatin A4 phosphate (120 mg/kg), a known vascular disrupting agent. Perfusion assessments were obtained with a pharmacokinetic Linear Reference Region Model (RKtrans and kep,T) and model-independent initial area under the curve assessments and compared using Wilcoxon signed-rank tests and Hedges' g effect sizes.
RESULTS: DCE-MRF demonstrated 1.3-to-5.1-fold larger effect sizes for RKtrans across all regions and timepoint comparisons, and 1.3-to-1.9-fold larger effect sizes for tumor rim kep,T compared to conventional DCE-MRI. RKtrans and kep,T at 3 h post-treatment in all regions, detected significant vascular recovery for whole tumor RKtrans and both whole tuomor and tumor rim for kep,T at 48 h, whereas DCE-MRI only detected significant changes at 3 h.
CONCLUSIONS: DCE-MRF's improved measurement precision and increased effect size translates directly to enhanced statistical power for detecting treatment-induced vascular changes, positioning it as a more reproducible tumor perfusion assessment for animal models and eventually cancer patients.
METHODS: Twenty female mice bearing orthotopic 4 T1 breast tumors were randomly assigned to DCE-MRF (n = 12) or conventional DCE-MRI (n = 8) cohorts. Both methods acquired matched spatial and temporal resolution (23-s) T1 measurements at baseline, 3 h, and 48 h post-treatment with combretastatin A4 phosphate (120 mg/kg), a known vascular disrupting agent. Perfusion assessments were obtained with a pharmacokinetic Linear Reference Region Model (RKtrans and kep,T) and model-independent initial area under the curve assessments and compared using Wilcoxon signed-rank tests and Hedges' g effect sizes.
RESULTS: DCE-MRF demonstrated 1.3-to-5.1-fold larger effect sizes for RKtrans across all regions and timepoint comparisons, and 1.3-to-1.9-fold larger effect sizes for tumor rim kep,T compared to conventional DCE-MRI. RKtrans and kep,T at 3 h post-treatment in all regions, detected significant vascular recovery for whole tumor RKtrans and both whole tuomor and tumor rim for kep,T at 48 h, whereas DCE-MRI only detected significant changes at 3 h.
CONCLUSIONS: DCE-MRF's improved measurement precision and increased effect size translates directly to enhanced statistical power for detecting treatment-induced vascular changes, positioning it as a more reproducible tumor perfusion assessment for animal models and eventually cancer patients.